/

INDP

Indaptus Therapeutics, Inc.Closed

2.39−0.05 −2.05%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.38 −0.42%

Open

2.44

Prev close

2.44

Day range

2.352.52

52-week range

0.92005.96

Volume

119.36K0.14×

Mkt cap

318.45M

P/E ttm

—

Fwd P/E

-1.72

EPS ttm

-6.15

Div yield

0.00%

Earnings

—

From 52w high

−59.90%

Price Chart

Yahoo Finance · delayed

INDPOct 13, 2026O 2.44H 2.52L 2.35C 2.39−0.05 (−2.05%)Vol 120.00K

SMA 502.06
SMA 2002.28

1Y change −39.03% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INDP Indaptus Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.72%
1 month: −13.72%
3 months: −9.13%
6 months: +2.58%
Year to date: −17.87%
1 year: −40.69%

Valuation & ownership

Market cap: 318.45M
Enterprise value: 306.90M
P/E (ttm): —
Forward P/E: -1.72
PEG ratio: —
Price / book: 28.12
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -6.15
EPS (forward): -1.39
Beta (5y monthly): 0.97
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 133.24M
Float: 23.70M
Short % of float: 2.00%
Short ratio (days): 0.56
Held by insiders: 82.41%
Held by institutions: 0.30%
Avg volume (3m): 860.71K
50-day average: 2.04
200-day average: 2.28
52-week change: −40.69%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 47.4
vs 50-day SMA: +15.84%
vs 200-day SMA: +4.88%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 16.76%
Realised vol (20d, ann.): 196.6%
From 52-week high: −59.90%
From 52-week low: +159.78%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Indaptus Therapeutics, Inc.

Yahoo Finance profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: New York, NY, United States
Website: indaptusrx.com
Officers: Mr. Junyi Dai CEO & Chairman
Mr. Yu Ding Chief Financial Officer

News

SEAS

Seasonality · INDP

2015–2026 · monthly returns

Strongest month Aug +3.66%Weakest month Oct −9.06%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-24.4	-6.2	-11.8	53.8	-37.1	70.5	-57.0	-11.2	100.9	3.9			−17.9%
2025	8.1	-7.8	-34.4	-16.4	-26.5	11.3	-22.5	-20.3	-55.8	12.2	-30.7	30.5	−87.7%
2024	-6.2	33.3	1.8	-3.1	9.2	-10.5	-3.8	-19.2	-24.7	-5.6	-12.8	-17.5	−52.2%
2023	22.1	-1.1	5.7	41.0	-37.5	17.2	8.4	39.1	-4.3	-15.8	-2.6	-22.1	+21.4%
2022	-12.5	-16.2	-4.3	-26.7	-13.7	3.2	8.8	-11.3	-14.3	-15.3	-0.5	-20.4	−74.6%
2021	18.3	7.6	-0.5	-7.3	-6.9	-8.0	-18.7	-6.8	-25.6	-8.6	-16.9	-4.2	−58.7%
2020	-41.8	2.7	-34.1	26.9	14.8	-1.4	48.1	-26.5	-18.2	-54.6	43.7	4.9	−65.5%
2019	4.0	13.5	-17.6	-16.8	-15.4	-15.9	-89.0	51.0	1.0	-1.2	-31.1	0.8	−93.4%
2018	21.4	-4.8	6.3	-18.6	-10.7	-4.3	-5.7	-4.8	43.0	5.1	16.5	9.0	+46.4%
2017	-11.5	-9.8	12.4	7.6	1.8	1.8	-4.4	17.4	39.8	-8.4	-27.4	-13.4	−9.6%
2016	-18.3	-12.2	7.2	-17.7	29.1	5.1	11.3	18.0	-2.6	-12.4	-1.9	12.9	+6.3%
2015									0.9	4.8	1.0	-9.6	−3.4%

INSD

Insider Activity · INDP

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jan 19, 2026	Ben-Tzvi AvrahamDirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Dec 21, 2025	Meckler Jeffrey AChief Executive Officer	Stock Award(Grant) at price 2.03 per share.	216.6K	$439.73K
Dec 21, 2025	Linscott Walt Addison Esq.Chief Operating Officer	Stock Award(Grant) at price 2.03 per share.	54.4K	$110.47K
Dec 21, 2025	Sassi NirChief Financial Officer	Stock Award(Grant) at price 2.03 per share.	26.8K	$54.32K
Dec 21, 2025	Newman Michael JamesOfficer and Director	Stock Award(Grant) at price 2.03 per share.	52.2K	$105.97K
Jul 24, 2025	Meckler Jeffrey AChief Executive Officer	Stock Award(Grant) at price 8.30 per share.	6.1K	$50.38K
Nov 24, 2024	Meckler Jeffrey AChief Executive Officer	Stock Award(Grant) at price 1.18 per share.	42.6K	$50.00K

INDP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INDP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Indaptus Therapeutics, Inc.

News

Seasonality · INDP

Insider Activity · INDP

Congress Trades · INDP

Investors Holding INDP

Investors Holding INDP

Congress Trades · INDP

Insider Activity · INDP

Seasonality · INDP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Indaptus Therapeutics, Inc.

News

Earnings & Dividends